Arrangement of Electronic Dissemination of Corporate Communications CF PharmTech, Inc. 長風藥業股份有限公司 (A joint stock company incorporated in the People's Republic of China with limited liability) （於中華人民共和國註冊成立的股份有限公司） (Stock Code 股份代號: 2652) 26 November 2025 Dear non-registered shareholder(s), Pursuant to Rule 2.07 of the Rules Governing The Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules") under the expansion of paperless listing regime and electronic dissemination of corpo ...

CF PharmTech, Inc. 長風藥業股份有限公司 (A joint stock company incorporated in the People's Republic of China with limited liability) （於中華人民共和國註冊成立的股份有限公司） (Stock Code: 2652) Solicitation of electronic contact details To ensure timely receipt of the Actionable Corporate Communications (Note) , the Company recommends you provide your email address by scanning your personalized QR code printed on the enclosed reply form (the "Reply Form"). Alternatively, you may sign and return the Reply Form to the Company's Hong Kong ...

格隆汇11月25日丨长风药业(02652.HK)公告，于2025年11月25日，董事会已考虑及批准建议实施公司20 名股东持有的本公司107,408,422股非上市内资股转换为公司H股("H股全流通")，占公司于本公告日期已 发行股本总额约26.1%。申请H股全流通的非上市内资股数目尚需向中国证监会备案。 ...

Core Viewpoint - Changfeng Pharmaceutical (02652) announced the board's approval to convert 107 million non-listed domestic shares held by 20 shareholders into H-shares, representing approximately 26.1% of the total issued share capital as of the announcement date [1] Group 1 - The conversion of shares requires filing with the China Securities Regulatory Commission [1] - The total number of non-listed domestic shares to be converted into H-shares is 107 million [1]

智通财经APP讯，长风药业(02652)发布公告，于2025年11月25日，公司董事会已考虑及批准建议实施公 司20名股东持有的公司1.07亿股非上市内资股转换为公司H股，占公司于本公告日期已发行股本总额约 26.1%。申请H股全流通的非上市内资股数目尚需向中国证监会备案。 ...

（於中華人民共和國註冊成立的股份有限公司） （股份代號：2652） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 CF PharmTech, Inc. 長風藥業股份有限公司 1 在取得所有相關批准（包括向中國證監會備案）及遵守所有適用法律、規則及法規 後，有關非上市內資股將轉換為本公司H股。本公司將向聯交所申請該等H股於聯 交所主板上市及買賣（「轉換及上市」）。根據本公司之公司章程，毋須於股東大會 上取得本公司股東進一步批准以批准轉換及上市。 於本公告日期，本公司尚未向中國證監會提交H股全流通的申請文件。本公司將 根據上市規則及適用法律法規的規定適時就H股全流通以及轉換及上市的進展作 出進一步公告。 H股全流通以及轉換及上市須遵守中國證監會、聯交所及其他境內外監管機 構規定的其他相關程序。本公司股東及潛在投資者於買賣本公司證券時務請 審慎行事。 內幕消息 本公司建議實施H股全流通 本公告乃由長風藥業股份有限公司（「本公司」連同其附屬公司統稱為「本集 ...

Core Viewpoint - Changfeng Pharmaceutical (02652) has announced that its board has approved a resolution regarding the proposal to grant the directors a general mandate to repurchase the company's issued H shares listed on the Main Board of the Hong Kong Stock Exchange [1] Group 1 - The proposal will be presented to the company's shareholders for consideration and approval at a special general meeting to be held at an appropriate time [1]

Core Viewpoint - Changfeng Pharmaceutical (02652) has announced that its board has reviewed and approved a proposal to grant general authority for the repurchase of its issued H shares listed on the Main Board of the Hong Kong Stock Exchange, which will be presented for consideration and approval at a special general meeting of shareholders to be held at an appropriate time [1] Group 1 - The board of Changfeng Pharmaceutical has approved a resolution regarding the repurchase of H shares [1] - The proposal will be submitted for shareholder approval at a special general meeting [1]

Core Viewpoint - Changfeng Pharmaceutical (02652) has announced a proposal to adopt a H-share incentive trust plan for 2025, aimed at aligning the interests of employees, management, and shareholders, while attracting, retaining, and motivating key talent to drive the company's sustainable development and long-term success [1] Summary by Relevant Categories - **Incentive Plan** - The H-share incentive plan is designed to align the interests of employees, management, and shareholders [1] - The plan aims to attract, retain, and motivate key talent within the company [1] - It is intended to reward contributions from employees and management, promoting the company's ongoing development [1] - **Long-term Strategy** - The initiative is part of the company's strategy to ensure sustainable growth and long-term success [1] - By implementing this plan, the company seeks to enhance its competitive position in the industry [1]

Core Viewpoint - Changfeng Pharmaceutical (02652) has announced a proposal to adopt a H-share incentive trust plan on November 12, 2025, aimed at aligning the interests of employees, management, and shareholders, while attracting, retaining, and incentivizing key talents to drive the company's sustainable development and long-term success [1] Group 1 - The H-share incentive plan is designed to align the interests of employees, management, and shareholders [1] - The plan aims to attract, retain, and incentivize key talents within the company [1] - The initiative is expected to contribute to the company's sustainable development and long-term success [1]